Phibro Animal Health (PAHC) reported $260.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.6%. EPS of $0.35 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $277.76 million, representing a surprise of -6.25%. The company delivered an EPS surprise of +52.17%, with the consensus EPS estimate being $0.23.While investors scrutinize revenue and earnings changes year-over-year and how they compa ...

Phibro Animal Health (PAHC) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 52.17%. A quarter ago, it was expected that this maker of animal health products and nutritional supplements would post earnings of $0.34 per share when it actually produced earnings of $0.41, delivering a sur ...

Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance TEANECK, N.J., November 6, 2024 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024 and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 20 ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share PAHC Nasdaq Stock Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran ...

Phibro Animal Health Corporation (PAHC) recently completed the acquisition of Zoetis Inc.’s (ZTS) medicated feed additive (MFA) product portfolio and certain water-soluble products. The latest acquisition comes with a lineup of products across cattle, swine and poultry, which will complement and expand Phibro’s species and product portfolios. This will help the company’s customers meet the highest standards of animal care, prevent diseases and enhance nutrition around the world. PAHC’s Likely Stock Trend Fo ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style S ...

Wall Street is sitting on its hands on Monday and Tuesday waiting for Alphabet, Microsoft, Apple, Amazon, and other mega-cap technology stocks to report their results in the final week of October.See the Zacks Earnings Calendar to stay ahead of market-making news. Amid the recent choppiness, some stocks are ripping to 52-week highs. Today we explore a screen that helps investors find soaring stocks trading near fresh highs that are also experiencing impressive upward earnings revisions activity, helping the ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Insulet (PODD) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision tren ...

Phibro Animal Health's (PAHC) diversified product portfolio and wide presence in key growth areas bolster our confidence in the stock. The stock carries a Zacks Rank #2 (Buy). Factors to Drive PAHC's Growth Phibro's existing operations and established sales, marketing and distribution network in over 80 countries provide ample scope to take advantage of global growth opportunities. Outside the United States, Phibro's global footprint extends to key high-growth regions (countries where the livestock producti ...

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive ...